Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2

Dear Editors,

The development of vaccines against SARS-CoV-2 has been extremely quick [1–6], and currently the Moderna mRNA-1273, Pfizer/BioNTech BNT162b2 mRNA, and the AstraZeneca/University of Oxford ChAdOx1-nCoV-19 chimpanzee adenovirus (ChAd) vector vaccines have gained regulatory approvals. Clinical trials with these vaccines have been performed, and their safety and efficacy information has been published [7, 8]. However, it is expected that with the initiation of large vaccination campaigns, some possible adverse effects would be observed.

The Israeli Ministry of Health has started a large-scale vaccination program in Israel, using the Pfizer/BioNTech BNT162b2 mRNA. In a period of three months following the initiation of the vaccination campaign, we have observed six cases of pityriasis rosea (PR) in the Department of Dermatology in the Hadassah Medical Center, which appeared after the administration of the first or second dose of the Pfizer/BioNTech BNT162b2 mRNA vaccine.

All the patients developed the typical PR rash, which was characterized by round-to-oval erythematous pruritic plaques, with trailing white scale at the periphery of the lesions, following the appearance of a herald patch (Table 1, Figure 1). The rash was distributed on the trunk, proximal limbs and occasionally on the lower neck. The rash appeared a short time (4.2 ± 3.1 days) after the first dose in three patients, and after the second dose in three patients. There were no systemic symptoms, such as fatigue, fever, or gastrointestinal symptoms. The rash resolved in 4–6 weeks in all patients.

Pityriasis rosea is a papulosquamous skin rash, which has been associated with reactivation of the human herpesvirus (HHV) 6/7. It is a self-limiting condition but can cause itching and discomfort [9]. Possible triggers for PR or PR-like rash include insect bites, viral infections (including SARS-CoV-2) [10] and many different drugs [9]. Interestingly, vaccinations have been reported to be an important triggering factor, and a PR-like rash has been reported after influenza, hepatitis B, smallpox, Bacillus Calmette-Guerin, diphtheria, and pneumococcus vaccines [11–13]. It was postulated that immune stimulation caused by the vaccine led to HHV reactivation, resulting in PR [4, 13, 14].

Cases of PR were described following SARS-CoV-2 mRNA vaccinations [15–17], and some of them were diagnosed as PR-like rash rather than genuine PR [18]. Actually, PR-like eruption has been suggested to be one of the patterns that were classified as cutaneous reactions to SARS-CoV-2 vaccination [19]. Nevertheless, the frequency of the PR-like eruption was much lower (4/9 %) than injection-site reaction (32.1 %), the most frequent cutaneous reaction.

While the fact that the patients did not have prodromal systemic symptoms might raise the possibility that the patients had a PR-like rash, the typical morphology of the lesions together with their distribution on the trunk after a herald patch with lack of oral involvement and only mild itch suggest that the rash is consistent more with PR [20, 21]. Unfortunately, we were not able to test for the presence of HHV-6/7 DNA in the plasma.

Although more information is needed to confirm the association between the Pfizer/BioNTech BNT162b2 mRNA vaccine and PR appearance, the alarming number of cases that emerged a short time after the vaccination should raise concern of such possible association.

Table 1 Details on patients who developed pityriasis rosea after BNT162b2 mRNA vaccine.

| Patient # | Gender | Age | Time of rash appearance | Location |
|-----------|--------|-----|-------------------------|----------|
| 1         | F      | 51  | 3 days after second dose of vaccine | Abdomen, chest, back, upper thighs, lower neck |
| 2         | M      | 20  | 3 days after first dose of vaccine | Back, abdomen, chest, upper limbs |
| 3         | M      | 26  | 2 days after second dose of vaccine | Back, upper and lower limbs, chest, abdomen |
| 4         | F      | 23  | 2 days after first dose of vaccine | Chest, abdomen, back, thighs |
| 5         | M      | 66  | 5 days after second dose of vaccine | Chest, abdomen, lower back |
| 6         | M      | 23  | 10 days after first dose of vaccine | Back, upper and lower limbs, chest, abdomen |

Abk.: W, weiblich; M, männlich.
Correspondence Clinical Letter

Conflict of interest
None.

Yuval Ramot¹, Krassimira Nanova², Sofia-Maria Faitatziadou¹, Dania Abu Assab¹, Yackov Berkun³, Abraham Zlotogorski¹

¹ Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel
² Clalit Health Services, Jerusalem, Israel
³ Department of Pediatrics, Hadassah Mount Scopus Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.

Correspondence to
Abraham Zlotogorski, MD
Department of Dermatology
Hadassah Medical Center
Hebrew University of Jerusalem, The Faculty of Medicine
Jerusalem, 9112001, Israel
E-mail: zloto@cc.huji.ac.il

References
1. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res 2020; 288: 198114.
2. Lurie N, Saville M, Hatchett R et al. Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020; 382: 1969–73.
3. Didona D, Buhl T, Yazdi AS. Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology. J Dtsch Dermatol Ges 2022; 20(2): 212–5.
4. Tomsitz D, Biedermann T, Brockow K. Skin manifestations reported in association with COVID-19 infection. J Dtsch Dermatol Ges 2021; 19: 530–4.
5. Grabbe S, Beissert S, Enk A. Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards? J Dtsch Dermatol Ges 2020; 18: 810–13.
6. Schön MP, Berking C, Biedermann T et al. COVID-19 and immunological regulations – from basic and translational aspects to clinical implications. J Dtsch Dermatol Ges 2020; 18: 795–807.
7. Baden LR, El Sahly HM, Essink B et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–16.
8. Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–15.
9. Leung AKC, Lam JM, Leong KF et al. Pityriasis rosea: An update on etiopathogenesis and management of difficult aspects. Indian J Dermatol Venereol 2016; 61: 375–84.
10. Baden LR, El Sahly HM, Essink B et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–16.
11. Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–15.
12. Leung AKC, Lam JM, Leong KF et al. Pityriasis rosea: An update on etiopathogenesis and management of difficult aspects. Indian J Dermatol Venereol 2016; 61: 375–84.
13. Papakostas D, Stavropoulos PG, Papafragkaki D et al. An atypical case of pityriasis rosea gigantea following COVID-19 infection. Case Rep Dermatol 2014; 6: 119–23.
14. Burmann SN, Bollmann A, Hohenstein S et al. No evidence for an increased risk of herpes zoster requiring full or partial hospitalization during the first year of the COVID-19 pandemic in Germany. J Dtsch Dermatol Ges 2022; 20(2): 206–11.
15. Shin SH, Hong JK, Hong SA et al. Pityriasis rosea shortly after mRNA-1273 COVID-19 vaccination. Int J Infect Dis 2022; 114: 88–9.
16. Temiz SA, Abdelmaksoud A, Dursun R et al. Pityriasis rosea following SARS-CoV-2 vaccination: A case series. J Cosmet Dermatol 2021; 20: 3080–4.
17. Marcantionio-Santa Cruz OY, Vidal-Navarro A, Pesque D et al. Pityriasis rosea developing after COVID-19 vaccination. J Eur Acad Dermatol Venereol 2021; 15(4): e246–7.
18. Gokcek GE, Oksum Solak E, Colgecen E. Pityriasis rosea like eruption: A dermatological manifestation of Coronavirus-COVID-19 vaccine. Dermatol Ther 2021; 25(5): 163526.
19. Catala A, Munoz-Santos C, Galvan-Casas C et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol 2022; 186: 142–52.
20. Drago F, Broccoli F, Ciccarese G. Comment on a case of pityriasis rosea shortly after Moderna COVID-19 vaccination. Int J Infect Dis 2022; 116: 166.
21. Drago F, Ciccarese G, Parodi A. Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them? JAAD Case Rep 2018; 4: 800–1.